Efficacy of sacituzumab govitecan versus treatment of physician’s choice in previously treated HR+ and HER2− mBC: a meta-analysis of TROPiCS-02 and EVER-132-002 trials
In conclusion, this meta-analysis confirms that SG significantly improves clinical outcomes in patients with HR+/HER2- mBC, including those pre-treated with CDK4/6i and fast-progressors when compared to TPC. These findings extend previous research, supporting the integration of SG into clinical practice guidelines at a global level for treating the HR+/HER2- mBC population irrespective of status and duration of prior CDK4/6i exposure.
Authors
- Rita Nanda (ORCID: https://orcid.org/0000-0001-5248-0876)
- Oleg Gluz (ORCID: https://orcid.org/0000-0001-6019-7544)
- Akanksha Sharma (ORCID: https://orcid.org/0009-0002-7840-3240)
- Wendy Verret
- Anandaroop Dasgupta
- Ankita Kaushik (ORCID: https://orcid.org/0000-0003-4411-9831)
- Hope S. Rugo (ORCID: https://orcid.org/0000-0001-6710-4814)
- Binghe Xu (ORCID: https://orcid.org/0000-0002-6863-5024)
- Barinder Singh
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- University of Chicago (US)
- Gilead Sciences (United States) (US)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
Publication Details
- Journal
- Therapeutic Advances in Medical Oncology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1177/17588359251320285
- Citations
- 5
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 7.59
Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Gilead Sciences
- Les Laboratories Pierre Fabre
- Seagen
- European Society for Medical Oncology